Drug Trial Radar · NCT07906145
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of QLS2416 injection in participants with autoimmune diseases (AID). The main questions it aims to answer are: • What is the safety and tolerability profile of single and multiple ascending doses of QLS2416 injection? This study consists of two parts. Participants will receive QLS2416 injection via subcutaneous administration in dose-escalation part and dose-expansion part. Safety assessments will be conducted throughout the study. Efficacy assessments will vary by disease indication.
Conditions
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis (RA)
- Primary Sjögren's Syndrome (pSS)
- Systemic Sclerosis (SSc)
Interventions
QLS2416 InjectionDrug
QLS2416 is a novel biologic agent administered via subcutaneous injection. Dose levels range from 0.025 mg to 6.0 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of QLS2416 InjectionTime frame: Up to 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.